MenACWY
Vaccines.
Understanding quadrivalent meningococcal conjugate vaccines, their capsular polysaccharide antigens, and the immune responses directed against serogroups A, C, W, and Y.
EXPLORE THE IMMUNOLOGY ↗
Four serogroups.
One vaccine class.
MenACWY vaccines are quadrivalent meningococcal conjugate vaccines designed to protect against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
These serogroups are distinguished by the chemical structure of their capsular polysaccharides. In conjugate vaccines, these polysaccharides are linked to carrier proteins to improve the quality of the immune response.
How conjugation
enhances immunity.
Protein conjugation enables the immune system to mount T-cell-dependent responses to bacterial capsular polysaccharide antigens.
Antigen presentation
B cells recognize capsular polysaccharide epitopes within the conjugated antigen.
T-cell help
Carrier-protein peptides support helper T-cell participation in the response.
Antibody production
Antibodies directed against capsular polysaccharides can contribute to complement-mediated bacterial killing.
Immune memory
Conjugation supports memory B-cell responses. Antibody persistence and booster needs vary with age and vaccine history.
Evaluating protective
immune responses.
Meningococcal vaccine immunogenicity is commonly investigated using serum bactericidal antibody assays, including assays with human or rabbit complement. Clinical trials also evaluate safety, antibody persistence, and booster responses.
Conjugate vaccine comparison
A randomized trial compared immunological responses to CRM-conjugated and tetanus toxoid-conjugated quadrivalent meningococcal vaccines.
READ THE STUDY ↗Adolescent immunogenicity
A randomized study investigated immunogenicity and safety of an ACWY tetanus toxoid conjugate vaccine in adolescents and young adults.
READ THE STUDY ↗Conjugate vaccine impact
Research on monovalent serogroup A conjugate vaccination demonstrates how vaccination can influence meningococcal carriage and population protection.
READ THE STUDY ↗The serogroup A population study evaluates a monovalent vaccine and illustrates conjugate-platform effects; it is not a direct effectiveness study of quadrivalent MenACWY vaccines.
Protection is
serogroup-specific.
MenACWY vaccination is used according to age- and risk-based recommendations. The indicated schedule depends on applicable national guidance and product labeling.
What does MenACWY cover?
Invasive meningococcal disease caused by serogroups A, C, W, and Y.
Does MenACWY protect against MenB?
No. Serogroup B protection requires a MenB-containing vaccine when indicated.
Why may boosters be recommended?
Circulating antibody levels can decline over time. Booster recommendations depend on age, risk, and vaccination history.
References and evidence.
- CDC — Types of Meningococcal Vaccines.
- CDC — Meningococcal Vaccine Recommendations.
- Randomized trial comparing CRM- and TT-conjugated quadrivalent meningococcal vaccines.
- MenACWY-TT immunogenicity and safety trial.
- Impact of a serogroup A conjugate vaccine on carriage and herd immunity.
Scientific educational content only. Vaccination decisions should follow current professional recommendations and regional immunization guidance.
MenB Vaccines
Explore recombinant proteins, antigen discovery, and serogroup B vaccine design.